MONALEESA III期晚期乳腺癌试验的循环肿瘤DNA汇总分析
本研究汇总MONALEESA三项III期试验中激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌患者的基线循环肿瘤DNA,采用下一代测序分析基因改变状态与无进展生存期的相关性,以寻找瑞波西利(ribociclib)疗效的潜在生物标志物。结果显示部分基因改变与瑞波西利较安慰剂更大的PFS获益相关,而高肿瘤突变负荷及部分基因改变者敏感性降低;作者认为结果属探索性,需验证。
要点
- ERBB2、FAT3、FRS2、MDM2、SFRP1、ZNF217改变与瑞波西利较安慰剂更大的PFS获益相关。
- 高肿瘤突变负荷及ANO1、CDKN2A/2B/2C、RB1改变者对瑞波西利的敏感性降低。
- 结果为探索性,作者认为需验证上述潜在标志物并开展前瞻性试验检验其临床价值。
核心结论
- 作者认为,尽管属探索性,结果提示与瑞波西利治疗应答改善相关的基因改变,并可能为CDK4/6抑制剂进展后存在可干预改变患者的治疗排序提供信息。
- 作者认为,需对本文识别的潜在生物标志物进行验证,并开展前瞻性试验检验其临床价值。
研究设计与样本
- MONALEESA系列III期试验评估细胞周期蛋白依赖性激酶(CDK)4/6抑制剂瑞波西利联合不同内分泌治疗,作为激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌一线或二线治疗的疗效与安全性。
- 采用下一代测序检测MONALEESA试验患者的基线循环肿瘤DNA,分析基因改变状态与无进展生存期(PFS)的相关性,以识别瑞波西利应答的潜在生物标志物。
- 本文为迄今瑞波西利在晚期乳腺癌中最大的汇总生物标志物数据集。
主要发现
- 识别出多个常见改变的基因;ERBB2、FAT3、FRS2、MDM2、SFRP1和ZNF217的改变与瑞波西利较安慰剂更大的PFS获益相关。
- 高肿瘤突变负荷(TMB)患者及ANO1、CDKN2A/2B/2C、RB1改变患者对瑞波西利的敏感性较安慰剂降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者称结果为探索性(exploratory)。
- 作者认为需对识别的潜在生物标志物进行验证。
- 作者认为需开展前瞻性试验检验这些标志物的临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Using the largest pooled biomarker dataset of the CDK4/6 inhibitor ribociclib in ABC to date, we identified potential biomarkers of response to ribociclib. PATIENTS AND METHODS: Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib. RESULTS: Multiple frequently altered genes were identified. Alterations in ERBB2, FAT3, FRS2, MDM2, SFRP1, and ZNF217 were associated with a greater PFS benefit with ribociclib versus placebo. Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo. CONCLUSIONS: Although exploratory, these results provide insight into alterations associated with the improved response to ribociclib treatment and may inform treatment sequencing in patients with actionable alterations following progression on CDK4/6 inhibitors. Validation of potential biomarkers identified here and development of prospective trials testing their clinical utility are warranted. GOV IDENTIFIERS: NCT01958021, NCT02422615, NCT02278120.
引用
- André F, Su F, Solovieff N, et al. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol. 2023. PMID: 37673211. doi:10.1016/j.annonc.2023.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。